4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Bullous Pemphigoid by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 86 ongoing clinical trials involving Bullous Pemphigoid
Of the 86 trials,36 trials are in Phase III
Furthermore, 32 trials are in Phase II/III

Number of ongoing Clinical Trials (for drugs) involving Bullous Pemphigoid by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Bullous Pemphigoid, a dermatology condition. The largest number of ongoing clinical trials for Bullous Pemphigoid is conducted in Europe. North America and Asia-Pacific are among some of the other prominent regions involved in Bullous Pemphigoid-related drug trials.

Bullous Pemphigoid related clinical trial sponsors

Akari Therapeutics Plc, ARTham Therapeutics Inc, and Reims University Hospital Centre are a few notable clinical trialsponsors involved in Bullous Pemphigoid. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Bullous Pemphigoid

Betamethasone butylate propionate (Antebate), Prednisolone (Delta-Cortef/ Deltacortril), and Betamethasone dipropionate (Rinderon-DP) are among the key marketed drugs involving Bullous Pemphigoid.

Betamethasone butylate propionate (Antebate) Is a corticosteroid, anti-inflammatory drug and an immunosuppressive agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as cream, ointment, lotion for topical application. Antebate is marketed for the treatment ofBullous Pemphigoid and several other indications including Alopecia Areata, Amyloidosis, Dermatosis, Sarcoidosis, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Atopic Dermatitis (Atopic Eczema), Psoriasis, Lymphoma, Epidermolysis Bullosa, Dermatitis Herpetiformis (Duhring's Disease), Edema, Erythema Multiforme, Hypertrophic Scars, Keloids, Prurigo. Antebatewas first approved in 2001 and is marketed in Japan by Torii Pharmaceutical Co Ltd.

Prednisolone (Delta-Cortef/ Deltacortril) is a hydroxysteroids derivative acts as a synthetic corticosteroid. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as delayed release injectable powder for solution for intramuscular, intraarterial, periarterial route of administration and as tablet for oral route of administration. Prednisolone is marketed for the treatment ofBullous Pemphigoid and several other indications including Osteoarthritis, Asthma, Lupus Nephritis, Seborrhea, Glomerulonephritis, Sarcoidosis, Juvenile Rheumatoid Arthritis, Vasculitis, and Adult Respiratory Distress Syndrome.Prednisolonewas first approved in 1955 and is marketed in the US, and India by Pfizer Inc, and in the UK by Alliance Pharmaceuticals Ltd.